EA201892051A1 - Фармацевтические композиции для лечения злокачественного новообразования - Google Patents

Фармацевтические композиции для лечения злокачественного новообразования

Info

Publication number
EA201892051A1
EA201892051A1 EA201892051A EA201892051A EA201892051A1 EA 201892051 A1 EA201892051 A1 EA 201892051A1 EA 201892051 A EA201892051 A EA 201892051A EA 201892051 A EA201892051 A EA 201892051A EA 201892051 A1 EA201892051 A1 EA 201892051A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
formation
pharmaceutical compositions
malignant non
malignant
Prior art date
Application number
EA201892051A
Other languages
English (en)
Russian (ru)
Inventor
Стивен Хоффман
Original Assignee
Тайм, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тайм, Инк. filed Critical Тайм, Инк.
Publication of EA201892051A1 publication Critical patent/EA201892051A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201892051A 2016-03-15 2017-03-15 Фармацевтические композиции для лечения злокачественного новообразования EA201892051A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662308341P 2016-03-15 2016-03-15
PCT/US2017/022386 WO2017160895A1 (en) 2016-03-15 2017-03-15 Pharmaceutical compositions for the treatment of cancer

Publications (1)

Publication Number Publication Date
EA201892051A1 true EA201892051A1 (ru) 2019-02-28

Family

ID=58428389

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892051A EA201892051A1 (ru) 2016-03-15 2017-03-15 Фармацевтические композиции для лечения злокачественного новообразования

Country Status (13)

Country Link
US (2) US20190091252A1 (cg-RX-API-DMAC7.html)
EP (1) EP3429583A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019508443A (cg-RX-API-DMAC7.html)
KR (1) KR20180116437A (cg-RX-API-DMAC7.html)
CN (1) CN109195601A (cg-RX-API-DMAC7.html)
AU (1) AU2017232348A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018068027A2 (cg-RX-API-DMAC7.html)
CA (1) CA3016446A1 (cg-RX-API-DMAC7.html)
EA (1) EA201892051A1 (cg-RX-API-DMAC7.html)
IL (1) IL261278A (cg-RX-API-DMAC7.html)
MX (1) MX2018011101A (cg-RX-API-DMAC7.html)
PH (1) PH12018501943A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017160895A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021000279A8 (pt) * 2018-07-09 2021-04-20 Tyme Inc formulações de redução de tumor e métodos de uso das mesmas
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
US20210106549A1 (en) * 2019-10-15 2021-04-15 Tyme, Inc. Pharmaceutical compositions and methods
CN115515575A (zh) * 2020-01-17 2022-12-23 迪美公司 用于调节癌症的酪氨酸衍生物
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029547A (en) * 1974-07-01 1977-06-14 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Biologically active substance, bestatin, and production thereof
CN1551767A (zh) * 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
JP2002326955A (ja) * 2001-04-27 2002-11-15 Nippon Kayaku Co Ltd 無再発生存期間延長剤
WO2013109610A1 (en) * 2012-01-17 2013-07-25 Steven Hoffman Pharmaceutical compositions and methods

Also Published As

Publication number Publication date
EP3429583A1 (en) 2019-01-23
MX2018011101A (es) 2018-11-22
US20200345753A1 (en) 2020-11-05
BR112018068027A2 (pt) 2019-01-08
WO2017160895A1 (en) 2017-09-21
PH12018501943A1 (en) 2019-06-17
JP2019508443A (ja) 2019-03-28
AU2017232348A1 (en) 2018-09-06
IL261278A (en) 2018-10-31
US20190091252A1 (en) 2019-03-28
CN109195601A (zh) 2019-01-11
CA3016446A1 (en) 2017-09-21
KR20180116437A (ko) 2018-10-24

Similar Documents

Publication Publication Date Title
CY1123557T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της δραστηριοτητας της αργινασης
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MX391501B (es) Agentes inductores de apoptosis
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EP4438117A3 (en) Tyk2 inhibitors and uses thereof
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA201691421A1 (ru) Гетероарилы и их применение
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201692437A1 (ru) Комбинация
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
EA201591599A1 (ru) Ингибиторы ido
EA201690306A1 (ru) Ингибиторы ido
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201792580A1 (ru) Ингибиторы ido